scholarly journals Identification of novel drug targets using model organisms

2009 ◽  
Vol 30 (2) ◽  
pp. 95
Author(s):  
Anthony Brzoska ◽  
Ryan Withers ◽  
Kylie Turner ◽  
Andrew Robinson ◽  
Nick Dizon ◽  
...  
Keyword(s):  
Drug Targets ◽  
Acquired Resistance ◽  
New Drugs ◽  
Model Organisms ◽  
Magic Bullet ◽  
The Public ◽  
Vancomycin Resistant ◽  
Novel Drug ◽  
General Community ◽  
Novel Drug Targets

Antibiotic resistance is an endemic problem within hospitals worldwide, and is becoming an increasing problem within the general community. Traditionally, physicians and the public have relied on the belief that as bacteria acquired resistance to one antibiotic, new drugs would be made available that could be used to combat those infections. The appearance of vancomycin-resistant Enterococcus (VRE) infections in the 1990s, combined with the withdrawal of funding for antimicrobial drug discovery and development by big Pharma, has led to the realisation that we can no longer assume that all infections can be treated with a ?magic bullet?. Recent years have seen the emergence of infections that are resistant to all clinically available antibiotics, including newly released drugs such as tigecycline. The cupboard is bare. Or at least it is heading that way.

scholarly journals Recent advances in the understanding and treatment of acute myeloid leukemia

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1196 ◽  
Author(s):  
Justin Watts ◽  
Stephen Nimer
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Drug Targets ◽  
Poor Prognosis ◽  
Clinical Development ◽  
New Drugs ◽  
Recent Advances ◽  
Novel Drug ◽  
Novel Drug Targets ◽  
Acute Myeloid

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals.

scholarly journals Serine Proteases of Malaria ParasitePlasmodium falciparum: Potential as Antimalarial Drug Targets

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Asrar Alam
Keyword(s):  
Antimalarial Drug ◽  
Serine Proteases ◽  
Drug Targets ◽  
New Drugs ◽  
Parasite Life Cycle ◽  
Mortality And Morbidity ◽  
Life Cycle Stages ◽  
Novel Drug ◽  
Potential Drug Targets ◽  
Novel Drug Targets

Malaria is a major global parasitic disease and a cause of enormous mortality and morbidity. Widespread drug resistance against currently available antimalarials warrants the identification of novel drug targets and development of new drugs. Malarial proteases are a group of molecules that serve as potential drug targets because of their essentiality for parasite life cycle stages and feasibility of designing specific inhibitors against them. Proteases belonging to various mechanistic classes are found inP. falciparum, of which serine proteases are of particular interest due to their involvement in parasite-specific processes of egress and invasion. InP. falciparum, a number of serine proteases belonging to chymotrypsin, subtilisin, and rhomboid clans are found. This review focuses on the potential ofP. falciparumserine proteases as antimalarial drug targets.

Novel drug targets in 2019

2020 ◽  
Vol 19 (5) ◽  
pp. 300-300 ◽  
Author(s):  
Sorin Avram ◽  
Liliana Halip ◽  
Ramona Curpan ◽  
Tudor I. Oprea
Keyword(s):  
Drug Targets ◽  
Novel Drug ◽  
Novel Drug Targets

scholarly journals Identification of Polo-like kinases as potential novel drug targets for influenza A virus

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Marie O. Pohl ◽  
Jessica von Recum-Knepper ◽  
Ariel Rodriguez-Frandsen ◽  
Caroline Lanz ◽  
Emilio Yángüez ◽  
...  
Keyword(s):  
Influenza A Virus ◽  
Drug Targets ◽  
Influenza A ◽  
Novel Drug ◽  
Novel Drug Targets

scholarly journals Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

10.3791/54738 ◽  
2016 ◽  
Author(s):  
Eamonn Morrison ◽  
Patty Wai ◽  
Andri Leonidou ◽  
Philip Bland ◽  
Saira Khalique ◽  
...  
Keyword(s):  
Functional Genomics ◽  
Cancer Cell ◽  
Drug Targets ◽  
Cell Spheroid ◽  
Novel Drug ◽  
Novel Drug Targets

scholarly journals Multi-omics data integration reveals novel drug targets in hepatocellular carcinoma

BMC Genomics ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Christos Dimitrakopoulos ◽  
Sravanth Kumar Hindupur ◽  
Marco Colombi ◽  
Dritan Liko ◽  
Charlotte K. Y. Ng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Targets ◽  
Mtor Signaling ◽  
Omics Data ◽  
Genetic Changes ◽  
Genetic Aberrations ◽  
Functional Consequences ◽  
Novel Drug ◽  
Novel Drug Targets ◽  
Omics Data Integration

Abstract Background Genetic aberrations in hepatocellular carcinoma (HCC) are well known, but the functional consequences of such aberrations remain poorly understood. Results Here, we explored the effect of defined genetic changes on the transcriptome, proteome and phosphoproteome in twelve tumors from an mTOR-driven hepatocellular carcinoma mouse model. Using Network-based Integration of multi-omiCS data (NetICS), we detected 74 ‘mediators’ that relay via molecular interactions the effects of genetic and miRNA expression changes. The detected mediators account for the effects of oncogenic mTOR signaling on the transcriptome, proteome and phosphoproteome. We confirmed the dysregulation of the mediators YAP1, GRB2, SIRT1, HDAC4 and LIS1 in human HCC. Conclusions This study suggests that targeting pathways such as YAP1 or GRB2 signaling and pathways regulating global histone acetylation could be beneficial in treating HCC with hyperactive mTOR signaling.

Sign in / Sign up

Export Citation Format

Share Document